Publication | Open Access

Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer

OncologyNovel TherapySelective Axl InhibitorMedicinePharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyPhase 1Lung Cancer